TC is a drug for correcting cognitive disorders in Alzheimer’s disease. The project aims to develop an innovative drug for treating Alzheimer’s disease (AD). The drug is an inhibitor of a new therapeutic target – STEP enzyme, which is expressed in brain tissue and is hyperactive in AD. The new highly safe drug is able to prevent the progression of AD and eliminate the development of associated cognitive disorders. The drug is the first in its class and is promising in the global market in the segment of drugs for AD treatment. The team includes experienced specialists in drug development and preclinical studies. The project partners are IPHAR R&D Center and the Novosibirsk Institute of Organic Chemistry of the Siberian Branch of the Russian Academy of Sciences.